Resiquimod Pegol

**Semantic type:** Pharmacologic Substance

**Definition:** A formulation composed of an agonist of toll-like receptor (TLR) type 7 and 8 (TLR7/8) that is attached to polyethylene glycol (PEG) via a hydrolyzable glycine linker, with potential immunostimulating and antitumor activities. Upon intratumoral (IT) administration, resiquimod pegol binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses against tumor-associated antigens (TAAs), which lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation. Pegylation of the TLR7/8 agonist enhances retention of this agent in the tumor microenvironment (TME), provides local sustained release of the TLR7/8 agonist, increases efficacy and reduces systemic exposure compared to the administration of the naked TLR7/8 agonist alone.

**Synonyms:** - NKTR 262 - NKTR-262 - NKTR262 - PEG-conjugated TLR7/8 Agonist NKTR-262 - RESIQUIMOD PEGOL - TLR 7/8 Agonist NKTR-262 - TLR7/TLR8 Agonist NKTR-262 - Toll-like Receptor 7/8 Agonist NKTR-262